2-(4-Butylsemicarbazono)thiazolidin-4-one | 149190-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 2-(4-Butylsemicarbazono)thiazolidin-4-one
• 英文别名: 1-Butyl-3-[(4-oxo-1,3-thiazolidin-2-ylidene)amino]urea
• CAS: 149190-13-6
• 化学式: C₈H₁₄N₄O₂S
• 分子量: 230.291
• InChiKey: RDCKRCBXCGDXBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0531812A1

  公开（公告）日：1993-03-17

  A novel Maillard reaction inhibitor containing at least one compound represented by formula (1) and the salts thereof; methods for producing the compounds of formula (1) and the salts thereof; a composition for inhibiting the Maillard reaction in living body comprising at least one compound of formula (1) and the salts thereof; and a use of said compound for preparing a pharmaceutical preparation for inhibiting the Maillard reaction in living body by administration of a compound of formula (1') or a salt thereof are disclosed.

  本发明公开了一种新型马氏反应抑制剂，其中至少含有一种由式（1）代表的化合物及其盐类；生产式（1）化合物及其盐类的方法；一种用于抑制活体内马氏反应的组合物，其中至少含有一种式（1）化合物及其盐类；以及所述化合物的用途，即通过服用式（1'）化合物或其盐类制备用于抑制活体内马氏反应的药物制剂。
• US5422360A
  申请人：——

  公开号：US5422360A

  公开（公告）日：1995-06-06
• [EN] AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B6<br/>[FR] COMPOSITION INHIBANT LA PRODUCTION DE PRODUITS TERMINAUX DE GLYCOSYLATION AVANCEE COMPRENANT UN INHIBITEUR DE LA REACTION DE MAILLARD ET LA VITAMINE B6
  申请人：——

  公开号：WO1998043649A2

  公开（公告）日：1998-10-08

  [EN] An AGE production inhibitor composition which inhibits the production of an AGE, causative of diabetic complications such as cataract, nephropathy, and retinopathy, is provided. The composition comprises (a) a Maillard reaction inhibitor, e.g., a compound represented by formula (1), (2) or (3), or a pharmaceutically acceptable salt thereof, and (b) vitamin B6 or a pharmaceutically acceptable salt thereof, wherein the individual groups are as described in the specification.
  [FR] L'invention concerne une composition inhibitrice de la production de produits terminaux de glycosylation avancée (AGE) inhibant la production d'un AGE, responsable de complications diabétiques telles que la cataracte, la néphropathie et la rétinopathie. La composition renferme (a) un inhibiteur de la réaction de Maillard, par exemple, un composé correspondant à l'une des formules (1), (2) ou (3), ou un sel pharmaceutiquement acceptable dudit composé, et (b) la vitamine B6 ou un sel pharmaceutiquement acceptable de celle-ci: (dans laquelle chacun des groupes est tel que décrit dans le descriptif).